Outcomes for Elderly Ovarian Cancer Patients Treated with Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)
Previously there has been a general misunderstanding about the benefit from intense therapy for elderly patients with ovarian cancer, resulting in a reluctance to follow normal treatment guidelines for older patients. Current therapy for ovarian cancer aims to achieve the most complete removal of cancer at the initial presentation.
Intense techniques involve cytoreductive surgery sometimes with prior chemo (neoadjuvant), with subsequent high temperature intraperitoneal chemo (HIPEC). In addition, following recurrence many patients have repeat surgery (salvage) and further HIPEC.
This study compared outcomes for patients younger and older than 65 years of age. Women who required salvage or repeat surgery did less well when older than 65. Otherwise for intense therapy the results are the same for younger and older patients. The authors suggest that age alone should not be an indicator of best treatment.
No comments:
Post a Comment